Advances in immunotherapy for stage III non-small cell lung cancer: moving immune checkpoint inhibitors to the front...
Editorial Commentary
Advances in immunotherapy for stage III non-small cell lung cancer: moving immune checkpoint inhibitors to the front lines concurrently with chemoradiotherapy?